期刊文献+

米诺环素与利福平联用对耐甲氧西林金黄色葡萄球菌的抗菌活性 被引量:4

Antiinfective activity of minocycline in combination with rifampin on methicillin-resistant Staphylococcus aureus in vitro
下载PDF
导出
摘要 目的评价米诺环素(四环素类半合成抗菌药)和利福平(抗结核药)对临床分离到的100株耐甲氧西林金黄色葡萄球菌(MRSA)的联合体外抗菌活性。方法采用棋盘法设计,用微量肉汤稀释法测定不同浓度组合的抗菌药物对100株MRSA最低抑菌浓度,计算部分抑菌浓度指数(FICI),判定联合效应。结果 2种抗菌药物联用后,对100株MRSA的M IC50显著降低,FICI分布:FICI≤0.5占92%;0.5<FIC I≤4占8%;FICI>4为0。结论米诺环素与利福平联用对100株MRSA体外抗菌效应表现为以协同作用为主;无关作用较少,无拮抗作用。 Objective To investigate the in vitro activity of minocycline combined with rifampin against 100 methicillin -resistant Staphylococcus aureus(MRSA) isolated from two China hospitals' clinical specimens of human infections. Methods The checkerboard method and broth microdilution method was used to determine the combinations activity against these strains. The susceptibility results for minocycline and rifampin were interpreted according to the guidelines of the CLSI, fractional inhibitory concentration was used to determine combination effection. Results The MIC50 was reduced significantly for the combination of minocycline and rifampin against MRSA compare to use minocycline and rifampin alone. The results of combination of minocycline and rifampin were 92% (92/100) synergism ; 8% ( 8/100 ) indifference ( minimum and maximum fractional inhibitory concentration index 0. 13 and 0. 53, respectively), and no antagonism. Conclusion Combinations of minocycline and rifampin may show synergism for most MRSA, and there was on antagonism, which may be a future therapeutic alternative for infections caused by MRSA.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2010年第11期813-816,共4页 The Chinese Journal of Clinical Pharmacology
基金 国家自然科学基金资助项目(30873127)
关键词 米诺环素 利福平 耐甲氧西林金黄色葡萄球菌 部分抑菌浓度指数 联合药敏 minocycline rifampin methicillin - resistant Staphylococcus aureus fractional inhibitory concentration index synergism
  • 相关文献

参考文献11

  • 1Antonia C. Kastoris,Petros I. Rafailidis,Evridiki K. Vouloumanou,Ioannis D. Gkegkes,Matthew E. Falagas.Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria[J].European Journal of Clinical Pharmacology.2010(4) 被引量:1
  • 2Thornsberry C.Ep idem iology of staphylococcal infections-a USAperspective[].J Chem otherapy.1994 被引量:1
  • 3Infectious D iseases Society ofAm erica.Bad Bug,No drugs.AsAn-tib iotic D iscovery Stagnates,a pub lic Health C risis B rews(M)[]..2004 被引量:1
  • 4FalagasME,G rammatikosAP,M ichalopou losA,et al.Potential ofold-generation antib iotics to address current need for new antib iot-ics[].Anti Infect Ther.2008 被引量:1
  • 5Goto Y,H iramatsu K,Nasu M.Improved efficacy w ith nonsimu lta-neous adm in istration of netilm icin and m inocycline againstm eth icil-lin-resistantStaphylococcus aureus in vitroandin vivomodels[].International Journal of Antimicrobial Agents.1999 被引量:1
  • 6Kadurugamuwa JL,S in LV,Yu J,et al.Non invasive optical imagingm ethod to evaluate postantib iotic effects on b iofilm infectionin vivo[].Antim icrob Agents Chem other.2004 被引量:1
  • 7Gomez EO,Jafary A,D ever LL.Daptomycin and rifamp in for thetreatm ent ofm eth icillin-resistantStaphylococcus aureusseptic pu l-monary emboli in the absence of endocard itis[].M icrob Drug Re-sist.2010 被引量:1
  • 8Sahm DF,Wash ington II JA.Antibacterial SusceptibilityTests:D ilu-tion M ethods[].Manual of C lin i-calM icrob iology.1995 被引量:1
  • 9Carmona P,,Rom E,Monte E.et al.Papel de linezolid en teraputica antim icrob iana[].Enferm Infecc M icrobiol C lin.2003 被引量:1
  • 10Pillai SK,Sakou las G,W ennersten C,et al.L inezolid resistance inStaphylococcus aureus:characterization and stab ility of resistant phe-notype[].J InfectD is.2002 被引量:1

同被引文献22

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部